Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

[Download PDF
Year : 2018  |  Volume : 64  |  Issue : 1  |  Page : 64-65  

Ocular surface leproma

J Ram1, N Kakkar2, G Gupta1, PC Gupta1,  
1 Department of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Histopathology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Dr. J Ram
Department of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh

How to cite this article:
Ram J, Kakkar N, Gupta G, Gupta P C. Ocular surface leproma.J Postgrad Med 2018;64:64-65

How to cite this URL:
Ram J, Kakkar N, Gupta G, Gupta P C. Ocular surface leproma. J Postgrad Med [serial online] 2018 [cited 2022 Dec 8 ];64:64-65
Available from:

Full Text

A 36-year-old male presented with a history of redness and a slowly growing swelling in his right eye since the past six months. Visual acuity was 20/20 both eyes. Slit-lamp biomicroscopy showed mild perilimbal congestion along with an inferotemporal vascularized, solid, rubbery, nontender limbal mass fixed to the underlying tissues. The mass was approximately 5 mm in diameter and was elevated 2 mm above the ocular surface. It was located between the 6 and 8'o clock position. The conjunctiva over the swelling was edematous and freely mobile with engorged conjunctival blood vessels traversing it. There was an area of sectoral interstitial keratitis adjacent to the lesion with deep and superficial vascularization of the cornea [Figure 1]a. Anterior segment was quiet and fundus unremarkable. General physical examination revealed bilateral thickened ulnar and popliteal nerves. Multiple nontender, nonhypoaesthetic, erythematous nodules were seen in the lumber region [Figure 2]. Slit-skin smears were positive for lepra bacilli. Excisional biopsy of the limbal mass showed subepithelial sheets of foamy histiocytes. In addition, numerous globi and fragmented lepra bacillary aggregates were observed, consistent with the diagnosis of histoid leprosy [Figure 1]b. Multibacillary multidrug (MDR-MB) therapy (rifampin, clofazimine, and dapsone) proposed by the World Health Organization (WHO) was initiated. After a year of follow-up, his perilimbal congestion and conjunctival edema resolved completely and nodular lesions on the lumbar region disappeared.{Figure 1}{Figure 2}

A leproma is a superficial, circumscribed, discrete granulomatous nodule rich in lepra bacilli. Its incidence in eye is reported to be 0.75–1% among lepromatous leprosy patients.[1] Most cases of lepromas in eye are reported to be in relation to the ciliary body with uveitis and rarely in limbus. Ocular involvement in leprosy may be due to primary infection of the ocular adenexa, direct invasion with gradual spread to the conjunctiva and cornea, or secondary to nerve involvement.[1] Histoid type of leprosy is an extremely rare variant of lepromatous leprosy. It is an uncommon form of multibacillary infection.[2] Histoid leprosy cases represent resistant bacilli and a highly active lepromatous disease process.[2] Mostly, the ocular clinical picture of leprosy is mixed with the involvement of several ocular structures.[3] However, in our case, the ocular involvement was confined to the limbus and cornea only, with no other ocular involvement.

The patients need to be treated with WHO recommended MDR-MB therapy. Follow-up is initially weekly for a month, then monthly for a year till the multidrug therapy is given, and then routine 6 monthly follow-up until 5 years. Treatment response is good and relapse rate is low; usually a single full course of therapy is sufficient. The WHO has estimated a risk of relapse of 0.77% for MB and 1.07% for paucibacillary (PB) patients 9 years after stopping MDT. Various other studies using person-years of observation have estimated relapse rates varying from 0.65 to 3.0% for PB and 0.02 to 0.8% for MB leprosy.[4] The majority of relapses occur in the first 3 years of treatment. If an individual does not relapse within the first 5–6 years, his/her risk of relapsing is negligible.[4]

Occurrence of such cases does not bode well for a country like India where leprosy was eradicated as a public health problem in 2005.[5] This case highlights the importance of maintaining a high index of suspicion for diagnosing leprosy in view of its declining incidence, especially in densely populated countries like India where such patients, if not diagnosed and managed timely, can act as potential reservoirs of infection in the community.

Declaration of patient consent

The authors certify that appropriate patient consent was obtained.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Francis IL, Ali NA, Telisinghe PU, Joshi N. Limbal leproma in lepromatous leprosy. Int J Ophthalmol 2011;4:678-81.
2Karthikeyan K. Histoid Leprosy. Am J Trop Med Hyg 2015;92:1085-6.
3Wedemeyer LL, Fuerst DJ, Perlman AR, McDonnell J, Rao NA. Fibrous histiocytoid leprosy of the cornea. Cornea 1993;12:532-6.
4The Leprosy Unit, WHO. Risk of relapse in leprosy. Indian J Lepr 1995;67:13-26.
5Palit A, Inamadar AC. Histoid leprosy as reservoir of the disease; a challenge to leprosy elimination. Lepr Rev 2007;78:47-9.

Thursday, December 8, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer